Big Pharma backs clinical trials industry in Quebec

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/dk_photos)
(Image: Getty/dk_photos)

Related tags: Glaxosmithkline, Pfizer, AbbVie, Takeda, Novartis, Merck, Servier, Roche, Clinical trials

Pharma giants including Pfizer, GSK, and Abbvie, renew their financial commitment to the early-stage clinical research in Quebec, Canada.

Catalis Québec is a is a public-private partnership developing tools to support early-stage clinical research. The organization “has the mandate of promoting Quebec's expertise in conducting early-stage clinical trials,”​ said Danika Laberge, general director of Catalis Quebec.

Catalis has partnerships with five Quebec-based health and social service organizations and eight pharmaceutical companies, including GlaxoSmithKline, Pfizer, AbbVie, Takeda, Novartis, Merck, Servier, and Roche, which have invested nearly CAD 1.6m ($1.19m) in the Catalis initiative since 2017.

The pharma companies this week announced renewed financial commitments to Catalis during the 2019 BIO International Convention.

“Catalis Quebec acts as a coordination office by rallying behind the efforts of its partners in order to stimulate private investment and promote excellence in the conduct of phase I, II and II-III clinical trials,”​ explained Laberge.

“Our projects benefit all life science research stakeholders and have positive economic and social impacts for Quebec and Canada,” ​she told us.

Projects announced so far this year include the development of standard operating procedures for ethical reviews of clinical research, an automated performance reporting tool, and a new system to manage and approve multicenter research projects.

Per ClinicalTrials.gov there are more than 1,400 studies currently underway in Canada. Laberge described Quebec as a preferred location “for its medical and scientific expertise, state-of-the-art infrastructure and research-friendly economic and regulatory environment,”​ said Laberge.

“Quebec has everything it needs to meet the growing demand,”​ she added, citing a $10bn investment from the Government of Quebec to modernize its health care facilities.

Said Laberge, “Several institutions have established Phase I clinical research units, which provides an environment conducive to early clinical trials.”

Related topics: Clinical Development, Phase I-II

Related news

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 01-Jun-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Related suppliers

Follow us

Products

View more

Webinars